Madison-based Archeus Technologies, a company developing radiopharmaceutical therapies, and the Wisconsin Alumni Research Foundation (WARF), the patenting and licensing arm of the University of Wisconsin-Madison, announced a strategic collaboration to advance ART-101, a prostate-specific, membrane antigen-targeting small molecule that could lead to improved outcomes for prostate cancer patients.
ART-101 was discovered and developed at the Advanced Radiotheranostics Lab at UW-Madison, led by Dr. Reinier Hernandez, assistant professor of medical physics at the University of Wisconsin School of Medicine and Public Health. Aided by support from WARF through the WARF Accelerator, ART-101 has demonstrated enhanced pharmacology in preclinical studies relative to FDA-approved prostate cancer treatment Pluvicto.
Through a collaboration agreement with WARF, Archeus Technologies will lead Phase 1 clinical development of this product, with trial initiation planned for 2025.
